Ram Waisbourd Biography and Net Worth

Insider of 89bio

Ram Waisbourd serves as Chief Operating Officer and Chief Business Officer of the Company. Prior to joining our company, Mr. Waisbourd served as Vice President of Strategy and Transformation, Global Research and Development, at Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from November 2016 to April 2018, where he was responsible for Teva research and development strategy, novel pipeline funding transactions and digital initiatives. Mr. Waisbourd also served as Vice President of Transformational Initiatives and Operations, Global Research and Development at Teva from September 2015 to October 2016 and Senior Director, Chief of the Research and Development Office from August 2012 to August 2015. Previously, Mr. Waisbourd served as Vice President of Business Development of XTL Biopharmaceuticals Ltd., a biotechnology company, and as Vice President of Biomedical Investments, an investment fund.

What is Ram Waisbourd's net worth?: The estimated net worth of Ram Waisbourd is at least $55,580.00 as of July 16th, 2021. Mr. Waisbourd owns 7,000 shares of 89bio stock worth more than $55,580 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Waisbourd may own. Learn More about Ram Waisbourd's net worth.
How do I contact Ram Waisbourd?: The corporate mailing address for Mr. Waisbourd and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Ram Waisbourd's contact information.
Has Ram Waisbourd been buying or selling shares of 89bio?: Ram Waisbourd has not been actively trading shares of 89bio over the course of the past ninety days. Most recently, Ram Waisbourd sold 7,000 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $5.70, for a transaction totalling $39,900.00. Learn More on Ram Waisbourd's trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 4 times. They purchased a total of 1,375,000 shares worth more than $20,925,450.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 4,477 shares worth more than $48,172.52. The most recent insider tranaction occured on December, 6th when CEO Rohan Palekar bought 5,000 shares worth more than $39,450.00. Insiders at 89bio own 2.8% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 12/6/2024.

Ram Waisbourd Insider Trading History at 89bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2022	Sell	7,000	$5.70	$39,900.00
12/16/2021	Sell	7,000	$11.48	$80,360.00
11/16/2021	Sell	7,000	$16.49	$115,430.00
10/18/2021	Sell	7,000	$17.49	$122,430.00
9/16/2021	Sell	7,000	$19.46	$136,220.00
7/16/2021	Sell	7,000	$16.80	$117,600.00	7,000
4/16/2021	Sell	7,000	$24.22	$169,540.00	7,000
3/16/2021	Sell	7,000	$24.20	$169,400.00	7,000
1/19/2021	Sell	7,000	$21.16	$148,120.00	7,000
12/16/2020	Sell	7,000	$27.04	$189,280.00	7,000

Ram Waisbourd Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $7.94

$6.60

$7.95

50 Day Range

MA: $8.45

$7.03

$10.45

2 Week Range

Now: $7.94

$6.43

$16.63

Volume

4,504,668 shs

Average Volume

980,337 shs

Market Capitalization

$842.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Most People Are Dead Wrong.

From Brownstone Research | Ad

Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.